

Session 1a: Modeling and Simulation in Support of New Modalities in Oncology Drug Development

The application of PK/PD modelling in the clinical development of BT5528 - a novel toxin delivery platform

Hongmei Xu, Russ Wada, Helen Kastrissios, Johanna Lahdenranta, Gavin Bennett, Zixu Wang, Phil Jeffrey






October 30 - November 2, 2022

Forward-looking statements


This presentation may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts", "goal," "intends," "may" "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. All statements other than statements of historical facts contained in this presentation are forward-looking statements, including statements regarding: our future plans; our current and prospective product candidates, planned clinical trials and preclinical activities; the potential of the Bicycle platform; the goals of the company's modeling activities with respect to plasma and tumor concentrations of BT5528 and MMAE; and, predictions regarding clinical concentrations of BT5528 and MMAE in tumor and in plasma respectively.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding future plans and strategies, our development plans, our preclinical and clinical results, our plans to initiate clinical trials and the designs of the planned trials and other future conditions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the ongoing COVID-19 pandemic, the risk that any one or more of our product candidates will not be successfully developed or commercialized, the risk of cessation or delay of any ongoing or planned clinical trials, the risk that we may not realize the intended benefits of our technology, including that we may not identify and develop additional product candidates for our pipeline, the risk that our predictions based on modelling activities will not prove to be accurate, the risk that our product candidates or procedures in connection with the administration thereof will not have the safety or efficacy profile that we anticipate, the risk that prior results will not be replicated or will not continue in ongoing or future studies or trials, the risk that we will be unable to obtain and maintain regulatory approval for our product candidates, and risks associated with our dependence on third-parties. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 4, 2022, as well as in other filings we may make with the SEC in the future, as well as discussions of potential risks, uncertainties and other important factors in our subsequent filings with the Securities and Exchange Commission. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.


Bicycles are a new therapeutic modality – bicyclic peptides



Bicycle Toxin Conjugates (BTCs) – preclinical data indicate high potency with high specificity



BT5528 is a first-in-class **BTC-targeting** EphA2



- BT5528 is a novel BTC that binds to tumor cells expressing cell surface EphA2
 - High expression across wide range of solid tumors
 - Toxin is released and retained in tumor cells resulting in tumor cell death and bystander killing

Article

- BT5528 is small and hydrophilic, allowing:
 - Rapid penetration into solid tumors
 - Short systemic exposure, renally excreted



Published OnlineFirst May 12, 2020; DOI: 10.1158/1535-7163.MCT-19-1092

MOLECULAR CANCER THERAPEUTICS | SMALL MOLECULE THERAPEUTICS

MMAE Delivery Using the *Bicycle* Toxin Conjugate BT5528 🕰 🗉

Gavin Bennett¹, Amy Brown¹, Gemma Mudd¹, Philip Huxley¹, Katerine Van Rietschoten¹, Silvia Pavan², Liuhong Chen¹, Sophie Watcham³, Johanna Lahdenranta⁴, and Nicholas Keen⁴

Aurora, CO


BT5528 development status

- BT5528 is being investigated in patients with advanced solid tumors historically known for expression of EphA2
- The goals of this modeling activity are to:
 - Develop an integrated model of plasma and tumor concentrations of BT5528 and MMAE in mice and in humans
 - Link tumor concentrations of MMAE to tumor regression in mice and in humans
 - Provide a framework to support RP2D decision-making for BT5528 and for other bicyclic peptides

Summary of data

Study	Species	Doses	N	BT5528 PK samples	MMAE PK samples	Tumor size data
Study 01	Mouse	0, 0.167, 0.5, 1.5 mg/kg	24	0	0	364
Study 02	Mouse	0.167, 0.5, 1.5 mg/kg	63	0	15 plasma 63 tumor	0
Study 03	Mouse	1.5 mg/kg	22	61 plasma 8 tumor	87 plasma 16 tumor	0
BT5528-100	Human	2.2, 4.4, 6.5, 8.5, 10 mg/m ²	64	1609 plasma	1605 plasma 5 tumor	155


Modeling schematic



Aurora, CO


October 30 - November 2, 2022

Mouse PBPK-based model



CL: clearance Kdeg: degradation rate constant Kel: rate of elimination Kin: rate constant from plasma to tumor Koff: dissociation rate constant Kon: association rate constant Kout: rate constant from tumor to plasma Kpt: rate of plasma to tissue Ktp: rate of tissue to plasma


Mouse PBPK model described plasma and tumor PK data well



- Median observed value
- Model prediction

October 30 - November 2, 2022


Mouse tumor model




- Substantial tumor suppression was seen from 0.5 mg/kg, however rebound was observed after treatment discontinuation
- Complete suppression was observed at 1.5 mg/kg dose

Simeoni, M. *et al. Cancer Res.* 64, 1094–1101 (2004) Claret, L. *et al. J. Clin. Oncol.* 27, 4103–4108 (2009)


Mouse tumor model describes the tumor volume data well



Human PopPK Model




The clinical PopPK model accurately describes the systemic concentrations of BT5528 and MMAE in cancer patients



Model prediction (dashed line) versus observed mean (±SD)

Human PopPK-PBPK Model



Assumptions


- Similar tubulin binding parameters (KD, Kon, Koff) across species.

CL: clearance Kdeg: degradation rate constant Kel: rate of elimination Kin: rate constant from plasma to tumor Koff: dissociation rate constant Kon: association rate constant Kout: rate constant from tumor to plasma Kpt: rate of plasma to tissue Ktp: rate of plasma to tissue Ktp: rate of tissue to plasma TMDD: target mediated drug disposition Vc: central volume of distribution for BT5528 Vm: central volume of distribution for MMAE

Note: CLt and Kin scaled allometrically by weight (coefficient of 0.75)


Aurora, CO

The linked PopPK-PBPK model also describes the clinical tumor concentrations of MMAE well



Concentrations of MMAE in tumor are predicted to exceed concentrations of MMAE in plasma

Predicted clinical plasma concentrations of BT5528 and MMAE and tumor concentrations of MMAE following a single dose BT5528 at 6.5 mg/m^2



Aurora, CO

Key findings of the PopPK-PBPK modeling

- BT5528 has a short terminal plasma half-life
- MMAE has rapid penetration into the tumor and is retained in the tumor through binding to tubulin
- Plasma concentrations of MMAE are a good surrogate for tumor concentrations of MMAE
 - validation based on extensive preclinical mouse data
 - emerging clinical data supports clinical translation

Bicycle[®]

Conclusions

- This preclinical and clinical PBPK-PopPK-tumor size modeling paradigm has enabled a prediction of tumor payload profiles for new BTCs
- This paradigm also supports dose selection and dose optimization that fully leverages both preclinical and clinical data, which is aligned with Project Optimus

Bicycle°

Acknowledgement


- Patients, their families and carers
- Investigators and clinical staff

QuanTx Consulting

- Russ Wada
- Helen Kastrissios

Bicycle Therapeutics team, especially...

- Kevin Lee
- Phil Jeffrey
- Dominic Smethurst
- Nicholas Keen
- Sebastien Hazard
- Johanna Lahdenranta
- Gavin Bennett
- Zixu Wang
- Punit Upadhyaya
- Joseph Tweed
- Adriana Domingo



Aurora, CO

October 30 - November 2, 2022